Cutting edge developments and novel targets in IBD: Microbiome in IBD
Best Practice & Research Clinical Gastroenterology · 2025
DOI: 10.1016/j.bpg.2025.102060 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2025. Verfasst von Sara Deleu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chronic Diseases, and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium. Electronic address: sara.deleu@kuleuven.be. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD), a non-communicable disease encompassing Crohn's disease and ulcerative colitis, is a chronic disorder with increasing prevalence and complex etiology. Emerging evidence highlights the gut microbiome's pivotal role in IBD pathogenesis, driving interest in microbiome-targeted therapeutic strategies. This narrative review explores the latest advancements in microbiome modulation for IBD management, encompassing antibiotics, prebiotics, probiotics, synbiotics, postbiotics, and fecal microbiota transplantation. Additionally, dietary interventions, physical activity, as well as non-bacterial microbiota components such as fungi, archaea, and bacteriophages are examined for their potential roles in restoring microbial equilibrium and mitigating intestinal inflammation. As research progresses, a multimodal approach integrating microbiota-targeted therapies with lifestyle modifications and conventional pharmacologic treatments may offer a personalized and effective strategy for IBD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chronic Diseases, and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium. Electronic address: sara.deleu@kuleuven.be.
- Department of Chronic Diseases, and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. Electronic address: joao.sab…
Förderung
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Deleu, S., & Sabino, J. (2025). Cutting edge developments and novel targets in IBD: Microbiome in IBD. Best Practice & Research Clinical Gastroenterology. https://doi.org/10.1016/j.bpg.2025.102060
Vancouver
Deleu S, Sabino J. Cutting edge developments and novel targets in IBD: Microbiome in IBD. Best Practice & Research Clinical Gastroenterology. 2025. doi:10.1016/j.bpg.2025.102060
BibTeX
@article{Deleu2025,
author = {Deleu, Sara and Sabino, João},
title = {Cutting edge developments and novel targets in IBD: Microbiome in IBD},
journal = {Best Practice & Research Clinical Gastroenterology},
year = {2025},
doi = {10.1016/j.bpg.2025.102060}
}
EUVIMED